Linezolid Zentiva

Linezolid, the active ingredient in Linezolid Zentiva, is an oxazolidinone presented as an intravenous solution for intravenous use. It treats serious Gram‑positive infections such as methicillin‑resistant Staphylococcus aureus (MRSA), vancomycin‑resistant Enterococcus (VRE), community‑acquired bacterial pneumonia, and skin and soft‑tissue infections in adults. The drug is given by controlled IV infusion, achieving rapid therapeutic levels by inhibiting bacterial protein synthesis.

GNH USA supplies Linezolid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and pharmacies worldwide through its global network.

Linezolid is used to treat infections caused by resistant Gram‑positive bacteria.

- Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective therapy for skin, bloodstream and pneumonia caused by MRSA. - Vancomycin‑resistant Enterococcus (VRE) infections: provides an option for serious VRE infections when alternatives are limited. - Community‑acquired bacterial pneumonia: achieves bacterial eradication in adult patients with typical and atypical pathogens. - Skin and soft‑tissue infections: resolves cellulitis, abscesses and wound infections caused by susceptible organisms.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Thrombocytopenia: mild reduction in platelet count. - Rash: skin erythema or maculopapular eruptions.

Serious or Rare Side Effects: - Myelosuppression: severe decrease in blood cell production, including anemia. - Peripheral neuropathy: nerve damage presenting as tingling or numbness. - Serotonin syndrome: risk when combined with serotonergic agents, leading to agitation, hyperthermia, and autonomic instability. - Lactic acidosis: rare metabolic disturbance with elevated lactate levels.

When using linezolid, several precautions should be observed to ensure safe therapy.

- Monitor blood counts: regular CBC testing to detect thrombocytopenia or anemia. - Assess renal and hepatic function: adjust therapy in patients with significant impairment. - Avoid concomitant serotonergic drugs: risk of serotonin syndrome requires alternative therapy. - Use caution in prolonged therapy: extended courses increase risk of myelosuppression and neuropathy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs) and monoamine oxidase inhibitors (MAOIs): may precipitate serotonin syndrome. - Rifampicin: strong inducer that markedly reduces linezolid plasma concentrations. - Tyramine‑rich foods and monoamine oxidase inhibitors: risk of hypertensive crisis when combined.

Moderate Interactions (Monitor Closely): - Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring. - Ethanol: may increase risk of disulfiram‑like reactions. - Anticonvulsants (e.g., carbamazepine, phenytoin): may lower linezolid levels, necessitating efficacy assessment.